Shots:

• The NMPA has approved Sulinno for the treatment of pJIA which is the fourth approved indication of the therapy in China. Earlier- Sulinno was approved for RA- PS- and psoriasis
• The launch of Sulinno has provided more Chinese patients with high-quality and relatively affordable adalimumab injection- bringing hope and opportunities to more patients
• Sulinno is a human anti-TNF-α mAb referencing Humira. The clinical results were published at the Inaugural Issue of The Lancet Rheumatology in 2019

Click Here ­ Ref: prnewswire | Image:  Innovent